We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Hldgs Plc | AQSE:SCLP.GB | Aquis Stock Exchange | Ordinary Share | GB00B63D3314 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -5.13% | 9.25 | 8.50 | 10.00 | 9.75 | 9.25 | 9.75 | 10,100 | 13:12:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSCLP
RNS Number : 9067V
Scancell Holdings Plc
06 December 2023
6 December 2023
Scancell Holdings plc
("Scancell" or the "Company")
PDMR Notification
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that further to the Company's announcement on the 1 December 2023 regarding the successful placing of ordinary shares of nominal value of 0.1 pence in the Company ("Shares") and the subscription for Shares by Dr Jean-Michel Cosséry and Professor Lindy Durrant, the following Shares were issued on 5 December 2023:
Dr Jean-Michel Cosséry 454,545 Professor Lindy Durrant 272,727
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities/person 1 closely associated a) Name Jean-Michel Cosséry ------------------------------- --------------------------------------------- Reason for the notification 2 ------------------------------------------------------------------------------ a) Position/status Chairman of Board and PDMR ------------------------------- --------------------------------------------- b) Initial notification/Amendment Initial notification ------------------------------- --------------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor ------------------------------------------------------------------------------ a) Name Scancell Holdings plc ------------------------------- --------------------------------------------- b) LEI 2138008RXEG856SNP666 ------------------------------- --------------------------------------------- Details of the transaction(s): section to be repeated for (i) 4 each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------------ a) Description of the Ordinary shares financial instrument, type of instrument ------------------------------- --------------------------------------------- b) Identification Code GB00B63D3314 ------------------------------- --------------------------------------------- c) Nature of the transaction Acquisition of ordinary shares ------------------------------- --------------------------------------------- d) Price(s) and volume(s) 454,545 ordinary shares at GBP0.11 per share ------------------------------- --------------------------------------------- e) Aggregated information - Aggregated volume N/A (single transaction) - Price ------------------------------- --------------------------------------------- f) Date of the transaction 5 December 2023 ------------------------------- --------------------------------------------- g) Place of the transaction Outside a trading venue ------------------------------- --------------------------------------------- Details of the person discharging managerial responsibilities/person 1 closely associated a) Name Lindy Durant ------------------------------- --------------------------------------------- Reason for the notification 2 ------------------------------------------------------------------------------ a) Position/status Executive Director and PDMR ------------------------------- --------------------------------------------- b) Initial notification/Amendment Initial notification ------------------------------- --------------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor ------------------------------------------------------------------------------ a) Name Scancell Holdings plc ------------------------------- --------------------------------------------- b) LEI 2138008RXEG856SNP666 ------------------------------- --------------------------------------------- Details of the transaction(s): section to be repeated for (i) 4 each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------------ a) Description of the Acquisition of ordinary shares financial instrument, type of instrument ------------------------------- --------------------------------------------- b) Identification Code GB00B63D3314 ------------------------------- --------------------------------------------- c) Nature of the transaction Acquisition of ordinary shares ------------------------------- --------------------------------------------- d) Price(s) and volume(s) 272,727 ordinary shares at GBP0.11 per share ------------------------------- --------------------------------------------- e) Aggregated information - Aggregated volume N/A (single transaction) - Price ------------------------------- --------------------------------------------- f) Date of the transaction 5 December 2023 ------------------------------- --------------------------------------------- g) Place of the transaction Outside a trading venue ------------------------------- ---------------------------------------------
-ENDS-
For further information, please contact: Scancell Holdings plc +44 (0) 20 3709 5700 Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7710 7600 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) Nick Adams/Nick Harland (Corporate Broking) Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500 Freddy Crossley/Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) ICR Consilium +44 (0) 20 3709 5700 Mary-Jane Elliott/Matthew Neal/Chris Welsh scancell@consilium-comms.com
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope (R) and ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody (R) ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab(R) ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab (R) ).
For further information about Scancell, please visit: https://www.scancell.co.uk/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHTFBTTMTJMBPJ
(END) Dow Jones Newswires
December 06, 2023 07:41 ET (12:41 GMT)
1 Year Scancell Chart |
1 Month Scancell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions